Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | AURKA | O14965 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | CASP1 | P29466 | 2/20 | 0.34 |
| ▸ | TTK | P33981 | 2/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.34 |
| ▸ | INCENP | Q9NQS7 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL18397976 | 0.78 | ALDH1A1 (0.42) | ALDH1A1KMT2AKDM4EMEN1LMNA | |
| SCHEMBL31408924 | 0.67 | CYP1A2 (0.36) | ALDH1A1KMT2AIDO1CYP1A2CYP3A4 | |
| SCHEMBL31748652 | 0.67 | AURKA (0.41) | PARP1ALDH1A1MAPTAURKAAURKB | |
| SCHEMBL6192864 | 0.67 | HDAC4 (0.38) | PARP1ALDH1A1MAPTKMT2AIDO1 | |
| SCHEMBL1159890 | 0.64 | BRAF (0.36) | ALDH1A1MAPTAURKBKMT2AIDO1 | |
| SCHEMBL11434636 | 0.63 | ALDH1A1 (0.36) | PARP1ALDH1A1AURKAIDO1HSD17B10 | |
| SCHEMBL11055567 | 0.62 | ALDH1A1 (0.45) | PARP1ALDH1A1MAPTKMT2AKDM4E | |
| SCHEMBL31747886 | 0.61 | AKT1 (0.42) | ALDH1A1AURKAAURKBINCENPKMT2A | |
| SCHEMBL17074654 | 0.61 | ALDH1A1 (0.31) | ALDH1A1KMT2ACYP1A2 | |
| SCHEMBL19358140 | 0.61 | TYMP (0.36) | PARP1ALDH1A1MAPTAURKATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516434-A1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2012-10-31 | — | — | EP | claimed |
| WO-2011079051-A1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-30 | — | — | WO | claimed |
| JP-2010502723-A | — | — | 2010-01-28 | — | — | JP | claimed |
| EP-2061444-A2 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, AMELIORATING, OR PREVENTING ALLERGY | Bausch & Lomb Incorporated (US) | 2009-05-27 | — | — | EP | claimed |
| EP-2051710-A2 | COMPOSITIONS AND METHODS FOR TREATING, REDUCING, AMELIORATING, OR ALLEVIATING POSTERIOR-SEGMENT OPHTHALMIC DISEASES | Bausch & Lomb Incorporated (US) | 2009-04-29 | — | — | EP | claimed |
| EP-2051736-A2 | COMPOSITIONS COMPRISING A DISSOCIATED GLUCOCORTICOID RECEPTOR AGONIST AND AN IMMUNOSUPPRESSIVE AGENT FOR TREATING DRY EYE | Bausch & Lomb Incorporated (US) | 2009-04-29 | — | — | EP | claimed |
| EP-2049112-A2 | TREATING INFECTIONS AND SEQUELAE THEREOF WITH COMBINED DISSOCIATED GLUCOCORTICOID RECEPTOR AGONISTS AND ANTI-INFECTIVE AGENTS | Bausch & Lomb Incorporated (US) | 2009-04-22 | — | — | EP | claimed |
| WO-2008033655-A2 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, AMELIORATING, OR PREVENTING ALLERGY | BAUSCH & LOMB INCORPORATED (US) | 2008-03-20 | — | — | WO | claimed |
| WO-2008021729-A2 | COMPOSITIONS AND METHODS FOR TREATING, REDUCING, AMELIORATING, OR ALLEVIATING POSTERIOR-SEGMENT OPHTHALMIC DISEASES | BAUSCH & LOMB INCORPORATED (US) | 2008-02-21 | — | — | WO | claimed |
| WO-2008021728-A2 | TREATING INFECTIONS AND SEQUELAE THEREOF WITH COMBINED DISSOCIATED' GLUCOCORTICOID RECEPTOR AGONISTS AND ANTI-INFECTIVE AGENTS | BAUSCH & LOMB INCORPORATED (US) | 2008-02-21 | — | — | WO | claimed |
| WO-2008005686-A2 | COMPOSITIONS COMPRISING A DISSOCIATED GLUCOCORTICOID RECEPTOR AGONIST AND AN IMMUNOSUPPRESSIVE AGENT FOR TREATING DRY EYE | BAUSCH & LOMB INCORPORATED (US) | 2008-01-10 | — | — | WO | claimed |
| US-20230295171-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | WELLS THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| EP-3665171-A1 | USE OF FUSED HETEROAROMATIC PYRROLIDONES FOR TREATMENT AND PREVENTION OF DISEASES IN ANIMALS | Bayer Animal Health GmbH (DE) | 2020-06-17 | — | — | EP | disclosed |
| WO-2019076817-A1 | USE OF FUSED HETEROAROMATIC PYRROLIDONES FOR TREATMENT AND PREVENTION OF DISEASES IN ANIMALS | BAYER ANIMAL HEALTH GMBH (DE) | 2019-04-25 | — | — | WO | disclosed |
| WO-2018053189-A2 | SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
| WO-2008033655-A2 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, AMELIORATING, OR PREVENTING ALLERGY | BAUSCH & LOMB INCORPORATED (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008027796-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING GLAUCOMA OR PROGRESSION THEREOF | BAUSCH & LOMB INCORPORATED (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008021729-A2 | COMPOSITIONS AND METHODS FOR TREATING, REDUCING, AMELIORATING, OR ALLEVIATING POSTERIOR-SEGMENT OPHTHALMIC DISEASES | BAUSCH & LOMB INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| EP-1583745-A1 | 1-PROPANOL AND 1-PROPYLAMINE DERIVATIVES AND THEIR USE AS GLUCOCORTICOID LIGANDS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004063163-A1 | 1-PROPANOL AND 1-PROPYLAMINE DERIVATIVES AND THEIR USE AS GLUCOCORTICOID LIGANDS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295171-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | PARP1 317/4885ALDH1A1 824/4885MAPT 4621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.